相关实验视频

Updated: Sep 14, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

改善肺癌瘤透性淋巴细胞 (TIL) 制造

Pamela K Noldner¹, Ying Zhou¹, Liliana Lyniv²

¹The Marcus Center for Cellular Cures, Duke University, Durham, North Carolina, USA.

|July 21, 2025

概括

针对非小细胞肺癌 (NSCLC) 的瘤透淋巴细胞 (TIL) 的优化制造现在更加具有成本效益. 简化方案为临床研究提供了优越的细胞毒性TIL.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

瘤透淋巴细胞 (TILs) 在治疗黑色素瘤方面表现有前途,并正在研究非小细胞肺癌 (NSCLC).
目前的TIL制造协议复杂且昂贵,需要优化以更广泛的临床应用.
该研究解决了对精简,成本效益和符合GMP的TIL生产的需求.

研究的目的:

简化和降低传统TIL制造的成本.
在优化过程中保持GMP合规,细胞产量和产品质量.
开发一个更高效的临床使用的TIL生产过程.

主要方法:

切除的肺瘤被培养以扩大TILs.
评估的介质配方,试剂,激活方法和冷保存.
将优化的TIL与标准协议 (莫菲特癌症中心) 产生的TIL进行了比较.

主要成果:

使用T细胞特异介质,人类AB血清和α-CD3/CD28纳米珠成功扩展了TILs.
培养时间从6-7周缩短到4周,产量约为200亿TIL.
优化的TILs表现出可比产量和表型,但对匹配的瘤细胞具有更高的细胞毒性.

结论:

传统的TIL制造可以优化成本效益和效率.
精简的过程产生了适合临床试验的数量的细胞毒性TILs.
这种优化的协议支持扩大TIL治疗NSCLC和其他癌症的范围.

关键词:

GMP制造制造业的制造业的制造业细胞治疗疗法细胞治疗疗法非小细胞肺癌的肺癌.瘤透的淋巴细胞

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.